Table 4. Cumulative Clinical Outcomes of Both Study Arms Through the 2-Year Follow-Up.

Clinical events	Follow-up
	In-hospital (N = 256)		1 year (N = 252)		2 years (N = 252)		P-value (at 2 years)
	BioMime (N = 170)	XIENCE (N = 86)	BioMime (N = 168)	XIENCE (N = 84)	BioMime (N = 168)	XIENCE (N = 84)	BioMime vs. XIENCE
Death, n (%)
Cardiac death	0	0	0	0	0	0	NA
Non-cardiac death	0	0	1 (0.6%)	0	2 (1.19%)	0	0.32
Myocardial infarction	1 (0.59%)	1 (1.16%)	2 (1.19 %)	4 (4.76%)	3 (1.79%)	5 (5.95%)	0.17
ID-TLR	0	0	10 (5.95%)	3 (3.57%)	10 (5.95%)	3 (3.57%)	0.45
ID-TVR (including TLR)	0	0	10 (5.95%)	3 (3.57%)	10 (5.95%)	3 (3.57%)	0.45
ID-TVR (non-TLR)	0	0	4 (2.38%)	2 (2.38%)	4 (2.38%)	2 (2.38%)	0.99
Stent thrombosis, n (%)
Definite or probable/probable	0	0	0	1 (1.19%)	0	1 (1.19%)	0.16
Total of three-point MACE	1 (0.59%)	1 (1.16%)	11 (6.55%)	7 (8.33%)	13 (7.74%)	8 (9.52%)	0.6170

Values are presented as n (%). ID-TLR: ischemia-driven target lesion revascularization; ID-TVR: ischemia-driven target vessel revascularization; MACE: major adverse cardiac event; N: number of patients.